At the same rate, another third (7/21) of the CUP cases in this cohort were refined to CCA after secondary review, all of which, again, had clinically actionable biomarkers, including IDH1 mutations or FGFR2 fusion. This evidence concerns the gene FGFR2 and cholangiocarcinoma.